Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients

Next Previous
Trial Profile

A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs BCG (Primary) ; Durvalumab (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms POTOMAC
  • Sponsors AstraZeneca

    • Most Recent Events

    • 04 Sep 2018 Planned End Date changed from 30 Jul 2024 to 25 Nov 2024.
    • 29 May 2018 Planned primary completion date changed from 13 Dec 2021 to 24 Nov 2021.
    • 29 May 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top